TITLE:
      Use of Activated Recombinant FVII in Spinal Surgery
SUMMARY:
      This trial is conducted in the United States of America (USA). The purpose of this clinical
      research trial is to understand how safe and effective Recombinant Activated FVII is for
      reducing bleeding and blood transfusions in patients undergoing spinal fusion surgery.
ELIGIBILITY CRITERIA:
      Inclusion Criteria:

          -  Elective spinal fusion surgery.

        Exclusion Criteria:

          -  History of thrombotic disorders (myocardial infarction, deep vein thrombosis,
             pulmonary embolism, stroke, disseminated intravascular coagulation or peripheral
             artery thrombosis)

          -  Any trauma within the last 3 months leading to hospitalization > 24 hours

          -  Angina or known coronary artery disease
